Heparin contamination: Lawmakers want answers

By Parija Kavilanz, senior writer


NEW YORK (CNNMoney) -- Lawmakers scolded the FDA for still not knowing what or who was behind the contamination of the blood-thinning drug Heparin, nearly three years after launching its investigation.

The contaminated drug led to the deaths of dozens of people in the U.S.

"It has been almost three years since the the FDA linked deaths and serious allergic reactions of patients to supplies of Heparin that came from China," Rep. Fred Upton (R-Mich.), wrote in a letter to Food and Drug Agency Commissioner Margaret Hamburg Wednesday.

Upton said the House Energy and Commerce committee, which he chairs, will conduct its own probe into the matter.

Neither the Chinese government nor the FDA has identified those responsible, even though FDA officials believe the contamination, with overly sulfated chondroitin sulfate, was economically motivated, according to the letter.

Upton said, "some of the individuals responsible for the adulteration are actively engaged in the Chinese pharmaceutical supply chain and pose a continuing threat to pharmaceutical products imported to the U.S."

Heparin is administered to about 12 million people in the U.S. annually, the committee said.

The agency has two weeks to submit all documents related to Heparin-related inspections conducted in China and possible sources of adulteration.

FDA spokeswoman Karen Riley said the agency will review the letter and respond directly to lawmakers.

FDA under the gun: Lawmakers are increasingly questioning why so many problems with drug manufacturing quality have gotten by safety regulators.

FDA officials appeared before lawmakers twice in 2010 regarding several recalls of Johnson & Johnson's (JNJ, Fortune 500) popular over-the-counter drugs such as Tylenol and Motrin.

The agency announced an investigation -- including a criminal probe -- into those recalls last summer but has not yet issued its findings.

While many drugs are manufactured in the U.S., a growing number are coming from China, which poses a challenge to regulators.

80% of all active pharmaceutical ingredients used in drugs sold in the U.S. now originate overseas, according to the U.S. Government Accountability Office. China is the top supplier of those ingredients.

The FDA typically inspects drug manufacturing plants in the U.S. every two years.

But with 1,000 or more drugmaking plants in China supplying U.S. companies, not every facility can be inspected on a three-year schedule, said Allan Coukell, director of medical safety with research firm Pew Health Group.

The FDA conducted 52 inspections in China in 2009, said agency spokeswoman Riley.

In China, the FDA only has 13 officials spread out in Beijing, Guangzhou and Shanghai. However, most inspections overseas are done by U.S.-based employees sent on site, she said. To top of page

Frontline troops push for solar energy
The U.S. Marines are testing renewable energy technologies like solar to reduce costs and casualties associated with fossil fuels. Play
25 Best Places to find rich singles
Looking for Mr. or Ms. Moneybags? Hunt down the perfect mate in these wealthy cities, which are brimming with unattached professionals. More
Fun festivals: Twins to mustard to pirates!
You'll see double in Twinsburg, Ohio, and Ketchup lovers should beware in Middleton, WI. Here's some of the best and strangest town festivals. Play
Index Last Change % Change
Dow 17,810.06 91.06 0.51%
Nasdaq 4,712.97 11.10 0.24%
S&P 500 2,063.50 10.75 0.52%
Treasuries 2.32 -0.02 -0.86%
Data as of 5:12am ET
Company Price Change % Change
Bank of America Corp... 17.12 0.12 0.71%
Kinder Morgan Inc 39.75 -0.17 -0.43%
Apple Inc 116.47 0.16 0.14%
Intel Corp 35.59 -0.36 -1.00%
Microsoft Corp 47.98 -0.72 -1.48%
Data as of Nov 21

Sections

This arrangement, announced Friday, illustrates how the lines have blurred between traditional TV networks and newfangled options like Netflix. More

The Obama administration is touting that its immigration action will boost wages. But the hike amounts to only $170 a year by 2024. More

Obama doesn't have the authority to create a startup visa, but part of his reform announcement could include a workaround for entrepreneurs: 'parole status.' More

Nearly half of all Americans say there's a chance they'll have to work during a holiday between Thanksgiving and New Year's, according to a new poll. And one in four say they'll have to work whether they want to or not. More

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.